The United States is conducting an investigation into Chinese pharmaceutical company WuXi AppTec for allegedly transferring data from American customers to the Beijing regime, which poses a risk to national security, according to Washington intelligence sources. This information was relayed to the Senate last month as lawmakers work on a biotech security bill targeting WuXi AppTec and other Beijing-based companies.
Last month, the Office of the Director of National Intelligence alerted the White House about Beijing’s scientific and technological advancements through intellectual property theft in order to gain economic and military advantages. In response to the allegations, a spokesperson for WuXi AppTec stated that the company complies with U.S. federal and state requirements and is not aware of any unauthorized transfers of customer data to China. They emphasized the importance of protecting their customers’ information and storing it according to their instructions.
China’s embassy in Washington rebuked Congress for claiming that WuXi AppTec posed a threat to national security without providing convincing evidence to support their allegations. The debate around potential risks associated with data transfers and intellectual property theft highlights ongoing concerns about the relationship between Chinese companies and the U.S. in sensitive sectors like biotechnology and pharmaceuticals.
The Senate has been working on a biotech security bill targeting WuXi AppTec and other Beijing-based companies for months now, but tensions remain high between China and the United States over this issue. The White House is particularly concerned about certain Chinese companies developing biotechnology that could be exploited by the Chinese military, which has led them to launch an investigation into WuXi AppTec
